NVS: Novartis AG
About
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Current Value
$102.801 Year Return
Current Value
$102.801 Year Return
Key Details
Market Cap
$202.05B
P/E Ratio
11.96
1Y Stock Return
7.15%
1Y Revenue Growth
-4.82%
Dividend Yield
3.17%
Price to Book
4.8
Strategies that include NVS
Stock's related to NVS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AZN | 49.43% | $197.82B | -0.75% | 2.33% |
| KO | 45.52% | $269.63B | +7.86% | 3.07% |
| TMO | 41.36% | $194.74B | +5.54% | 0.30% |
| SJW | 40.82% | $1.83B | -14.15% | 2.89% |
| SRE | 40.41% | $59.15B | +28.15% | 2.62% |
| SNY | 40.24% | $120.34B | +3.11% | 4.25% |
| GSK | 39.90% | $68.24B | -5.43% | 4.71% |
| EPR | 39.65% | $3.38B | -0.51% | 7.62% |
| ENB | 39.14% | $93.61B | +26.93% | 6.23% |
| CMS | 39.04% | $20.49B | +20.66% | 3.01% |
| KMB | 39.03% | $45.22B | +11.57% | 3.58% |
| PM | 38.90% | $201.41B | +39.59% | 4.05% |
| ETR | 38.80% | $32.14B | +49.00% | 3.05% |
| MDLZ | 38.75% | $85.41B | -10.00% | 2.73% |
| AWR | 37.51% | $3.22B | +7.55% | 2.09% |
| ABT | 37.51% | $203.16B | +14.93% | 1.88% |
| AWK | 37.25% | $26.93B | +5.63% | 2.17% |
| WTRG | 37.16% | $10.70B | +12.02% | 3.25% |
| FE | 36.96% | $23.96B | +10.41% | 4.05% |
| POR | 36.54% | $4.95B | +14.95% | 4.16% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UMC | -<0.01% | $17.49B | -11.20% | 6.65% |
| DLTR | -0.01% | $13.95B | -44.11% | 0.00% |
| VSAT | 0.01% | $876.93M | -65.78% | 0.00% |
| FROG | 0.04% | $3.34B | +11.67% | 0.00% |
| HEAR | -0.04% | $300.79M | +44.04% | 0.00% |
| ZI | -0.05% | $3.40B | -28.47% | 0.00% |
| FTI | -0.06% | $12.24B | +36.61% | 0.87% |
| NTIC | -0.06% | $132.27M | +24.98% | 2.02% |
| OPRA | -0.06% | $1.75B | +63.06% | 4.03% |
| HOOD | -0.07% | $31.15B | +341.60% | 0.00% |
| WMG | 0.07% | $17.06B | +1.39% | 2.63% |
| TRIP | -0.08% | $1.87B | -29.46% | 0.00% |
| SGML | 0.09% | $1.54B | -51.62% | 0.00% |
| ALTG | -0.09% | $236.78M | -29.08% | 3.22% |
| ASTS | 0.11% | $4.31B | +506.50% | 0.00% |
| GGAL | 0.11% | $6.81B | +291.69% | 0.50% |
| LI | -0.14% | $18.90B | -43.16% | 0.00% |
| INSM | -0.15% | $13.19B | +202.50% | 0.00% |
| XOS | -0.18% | $30.51M | -57.24% | 0.00% |
| AMRK | -0.20% | $697.61M | +7.29% | 2.67% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| POWL | -18.71% | $3.74B | +275.35% | 0.29% |
| FATBB | -15.31% | $81.94M | -12.91% | 11.69% |
| CLS | -14.91% | $10.10B | +223.71% | 0.00% |
| CAMT | -13.90% | $3.40B | +16.39% | 0.00% |
| DASH | -12.79% | $73.18B | +86.24% | 0.00% |
| HUSA | -12.74% | $16.69M | -11.56% | 0.00% |
| VRT | -12.72% | $52.90B | +230.61% | 0.07% |
| ALAB | -12.01% | $15.10B | +164.39% | 0.00% |
| ARM | -11.92% | $139.85B | +126.83% | 0.00% |
| GEV | -10.96% | $93.72B | +159.05% | 0.00% |
| GCT | -10.79% | $983.16M | +147.95% | 0.00% |
| GEO | -10.01% | $3.97B | +204.07% | 0.00% |
| DDOG | -9.75% | $45.32B | +19.19% | 0.00% |
| CRWD | -9.63% | $86.61B | +69.05% | 0.00% |
| CFLT | -9.59% | $9.28B | +49.05% | 0.00% |
| ANF | -9.58% | $7.28B | +92.60% | 0.00% |
| VIRT | -9.57% | $3.17B | +110.38% | 2.60% |
| CVLT | -9.31% | $7.37B | +136.34% | 0.00% |
| RDDT | -9.08% | $24.08B | +303.41% | 0.00% |
| PUBM | -8.89% | $739.82M | -2.82% | 0.00% |
ETF's related to NVS
News
Yahoo
The pharma company raised its guidance on revenue growth of its key treatments and expected drug launches, and now expects annual currency-adjusted sales to grow by 6% through 2028.
Yahoo
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ peak sales potential and 15+ near-term submission-enabling readouts 30+ high-value medicines in the pipeline expected to support continued mid-single digit sales growth beyond 2029 Basel, November 21, 2024 – Today Novartis announced an upgrade to its mid-term guidance, in advance of its Meet Novartis M
Fintel
Erste Group Downgrades Novartis AG - Depositary Receipt () (NVS)
SeekingAlpha
Autolus Therapeutics' AUCATZYL shows strong potential despite safety concerns. Find out why AUTL stock is a Buy.
SeekingAlpha
The fund posted returns of 5.38% (Institutional shares) and 5.32% (Investor A shares, without sales charge) for the third quarter of 2024.
SeekingAlpha
The fund posted returns of 6.75%Â (Institutional shares) and 6.68%(Investor A shares, without sales charge) for the third quarter of 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.